News
-
-
-
PRESS RELEASE
Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease
Alfasigma partners with Innovative Molecules for exclusive rights to Adibelivir for HSV Encephalitis treatment, a rare condition. Financial terms and patient impact explained